In our rapidly evolving therapeutic landscape, there is a critical need for cohesive infrastructure that helps track what happens when individuals are on more than one therapy and how we can continue to evolve standards of care in this new era.

This is why PPMD is proud to introduce and begin development of the Dystrophinopathy Clinical Research Network (DCRN), a groundbreaking collaboration of researchers, clinicians, regulators, advocates, and citizen scientists that will leverage existing Duchenne clinical networks, multidisciplinary expertise, and supportive infrastructure to revolutionize how we use add-on therapies to slow progression and redefine standards of care.

What is the DCRN?

The Dystrophinopathy Clinical Research Network (DCRN) is a network of care centers and research institutions united to advance collaborative research and data sharing for Duchenne and Becker muscular dystrophy. By fostering partnerships across disciplines, the DCRN streamlines real world data collection, ensuring that all families benefit sooner from clinical expertise and cutting-edge innovations.

This network reflects PPMD’s holistic approach to tackling Duchenne and Becker. It is more than a series of clinics; it is a community of experts dedicated to developing new standards in care and research. To move further, faster. The DCRN is new research for a new reality.

Why is the DCRN Important?

Sharing Knowledge and Data: Collaboration is key. The DCRN will enable experts to share vital insights and data, breaking down silos that can delay progress. This data sharing fosters innovation, ensuring that breakthroughs from one learning benefit the entire community. 

Advancing Care Standards: The DCRN won’t just advance research—it will also improve care. By focusing on real world data, we aim to ensure that every person living with Duchenne or Becker receives cutting-edge, evidence-based care to preserve function, and improve quality of life.

Accelerating Clinical Trials: The DCRN will facilitate faster, more efficient clinical trials. By bringing together a network of committed physician researchers, we can coordinate multi-site studies, compare previously disparate cohorts, reduce redundancies, and ensure trials are designed with families in mind.

Looking to the Future

The DCRN represents the next step in advancing the research evolution and PPMD’s drive to move science further, faster. PPMD’s DCRN will transform how we analyze data and establish new standards of care for Duchenne and Becker in a growing landscape of approved and investigational therapies.

Developing the DCRN from concept to reality is not possible without the steadfast commitment of our generous supporters. Together, we are creating a brighter future for every individual and family impacted by Duchenne and Becker.